Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded […]readmore
Tags : Lannett
PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab Published: Mar 12, 2021 | Tags: PhaseBio, Signs, Supply, Agreement, BioVectra, Support, Development, Commercialization, Bentracimab […]readmore
Shots: The US FDA provide feedback on the pivotal trial protocol and statistical analysis plan (SAP) for the development program of biosimilar insulin glargine candidate, which the company plan to […]readmore
Visby’s POC COVID-19 Test Receives the US FDA’s EUA for Use in CLIA Waived Settings Published: Feb 12, 2020 | Tags: Visby, POC, COVID-19, Test, Receives, US, FDA, EUA, Use, CLIA, […]readmore
Shots: The companies collaborated to co-develop Insulin aspart while Lannett granted exclusive US commercialization rights of insulin aspart to HEC Lannett will fund the clinical development requirements and will manage […]readmore
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, […]readmore
1. Medtronic Receives CE Mark for MiniMed 780G Insulin Pump to Treat Type 1 Diabetes Published: Jun 11, 2020 | Tags: Medtronic, Receives, CE, Mark, MiniMed 780G, Insulin Pump, Treat, […]readmore
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency In Dec, 2019 Kamada signed a deal with Alvotech for commercialization of […]readmore
Shots: The first clinical study in humans involves evaluation of PK/PD of the Lannett/HEC-insulin glargine vs the reference product, Sanofi’s US approved Lantus after a single SC dose in 27 […]readmore